Form 4: Septerna COO Elizabeth Bhatt Executes Stock Transactions

Septerna President and COO Elizabeth Bhatt exercised stock options and sold shares under a pre-arranged 10b5-1 plan.

Summary

• Elizabeth Bhatt, President and COO of Septerna, Inc., exercised options to acquire 4,000 shares of common stock at a price of $6.81 per share.
• Following the acquisition, the reporting person sold a total of 4,000 shares in three separate transactions on April 15, 2026.
• The sales were executed at weighted average prices of $23.7558, $25.2394, and $25.8623 per share.
• The transactions were conducted pursuant to a Rule 10b5-1 trading plan adopted on October 20, 2025.
• The reporting person retains beneficial ownership of 174,209 shares of common stock following these transactions.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event, as the transactions were executed under a pre-planned 10b5-1 arrangement, which is standard corporate practice.

Positives

• The transactions were executed under a pre-established Rule 10b5-1 plan, indicating a systematic approach to liquidity rather than reactive selling.
• The exercise of options demonstrates continued alignment with the company's equity incentive structure.

Negatives

• The transaction results in a net reduction of the executive's direct shareholding in the company.

Risks

• Future share price volatility may impact the value of remaining holdings.
• Reliance on Rule 10b5-1 plans does not eliminate the potential for negative market perception regarding insider selling.

Future Outlook

No specific forward-looking guidance regarding company operations was provided in this filing, as it is a standard disclosure of insider transaction activity.

Industry Context

StockSavvy.ai notes that insider selling via 10b5-1 plans is a standard practice for executives in the biotechnology sector to manage personal financial planning and diversify holdings, and is generally viewed as neutral by the market when pre-planned.

Comparison to Industry Standards

• The use of Rule 10b5-1 plans is the industry standard for corporate officers to avoid potential conflicts of interest or accusations of insider trading.
• The volume of shares sold relative to the total holdings (174,209 remaining) is consistent with typical executive diversification strategies.

Stakeholder Impact

• Minimal impact expected on shareholders as the sales were pre-planned and represent a small portion of the executive's total holdings.

Next Steps

• Continued monitoring of future Form 4 filings for further insider activity.

Key Dates

Keywords

Septerna, SEPN, Insider Trading, Form 4, Biotech, Equity Compensation